Literature DB >> 7479939

The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro.

J Fick1, F G Barker, P Dazin, E M Westphale, E C Beyer, M A Israel.   

Abstract

Herpes simplex virus thymidine kinase (HSV-tk)/ganciclovir (GCV) viral-directed enzyme prodrug gene therapy causes potent, tumor-selective cytotoxicity in animal models in which HSV-tk gene transduction is limited to a minority of tumor cells. The passage of toxic molecules from HSV-tk+ cells to neighboring HSV-tk- cells during GCV therapy is one mechanism that may account for this "bystander" cytotoxicity. To investigate whether gap junction-mediated intercellular coupling could mediate this bystander effect, we used a flow cytometry assay to quantitate the extent of heterocellular coupling between HSV-tk+ murine fibroblasts and both rodent and human tumor cell lines. Bystander tumor cytotoxicity during GCV treatment in a coculture assay was highly correlated (P < 0.001) with the extent of gap junction-mediated coupling. These findings show that gap junction-mediated intercellular coupling contributes to the in vitro bystander effect during HSV-tk/GCV therapy and that retroviral transduction of tumor cells is not required for bystander cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479939      PMCID: PMC40573          DOI: 10.1073/pnas.92.24.11071

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  'Bystander killing' induces apoptosis and is inhibited by forskolin.

Authors:  Y Samejima; D Meruelo
Journal:  Gene Ther       Date:  1995-01       Impact factor: 5.250

2.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy.

Authors:  W L Bi; L M Parysek; R Warnick; P J Stambrook
Journal:  Hum Gene Ther       Date:  1993-12       Impact factor: 5.695

3.  Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors.

Authors:  D Barba; J Hardin; M Sadelain; F H Gage
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

4.  Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors.

Authors:  E J Boviatsis; M Chase; M X Wei; T Tamiya; R K Hurford; N W Kowall; R I Tepper; X O Breakefield; E A Chiocca
Journal:  Hum Gene Ther       Date:  1994-02       Impact factor: 5.695

5.  Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA.

Authors:  R G Vile; I R Hart
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

6.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

Authors:  S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

7.  Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection.

Authors:  S J Tapscott; A D Miller; J M Olson; M S Berger; M Groudine; A M Spence
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

8.  Regression of established macroscopic liver metastases after in situ transduction of a suicide gene.

Authors:  M Caruso; Y Panis; S Gagandeep; D Houssin; J L Salzmann; D Klatzmann
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

9.  The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats.

Authors:  Z Ram; S Walbridge; T Shawker; K W Culver; R M Blaese; E H Oldfield
Journal:  J Neurosurg       Date:  1994-08       Impact factor: 5.115

10.  Thymidine kinase-mediated killing of rat brain tumors.

Authors:  D Barba; J Hardin; J Ray; F H Gage
Journal:  J Neurosurg       Date:  1993-11       Impact factor: 5.115

View more
  35 in total

1.  Connexin43 increases the sensitivity of prostate cancer cells to TNFalpha-induced apoptosis.

Authors:  Min Wang; Viviana M Berthoud; Eric C Beyer
Journal:  J Cell Sci       Date:  2007-01-02       Impact factor: 5.285

2.  Combination gene delivery of the cell cycle inhibitor p27 with thymidine kinase enhances prodrug cytotoxicity.

Authors:  X Danthinne; K Aoki; A L Kurachi; G J Nabel; E G Nabel
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

3.  Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach.

Authors:  Mai Johnson; Makoto Sato; Jeremy Burton; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Mol Imaging       Date:  2005 Oct-Dec       Impact factor: 4.488

Review 4.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

5.  Intercellular trafficking and cytotoxicity of recombinant HSV-1 thymidine kinase fused with HSV-2 US11 RXP repeat peptide.

Authors:  Chenhong Luo; Akihiro Nawa; Youhei Yamauchi; Shinichi Kohno; Youko Ushijima; Fumi Goshima; Fumitaka Kikkawa; Yukihiro Nishiyama
Journal:  Virus Genes       Date:  2006-08-22       Impact factor: 2.332

6.  TK gene combined with mIL-2 and mGM-CSF genes in treatment of gastric cancer.

Authors:  Shan-Yu Guo; Qin-Long Gu; Zheng-Gang Zhu; He-Qun Hong; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

7.  Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir.

Authors:  L Yang; R Hwang; L Pandit; E M Gordon; W F Anderson; D Parekh
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

8.  Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease.

Authors:  Donna N Douglas; Toshiyasu Kawahara; Banu Sis; David Bond; Karl P Fischer; D Lorne J Tyrrell; Jamie T Lewis; Norman M Kneteman
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

Review 9.  Gene therapeutic approaches for medullary thyroid carcinoma treatment.

Authors:  Matthias Drosten; Brigitte M Pützer
Journal:  J Mol Med (Berl)       Date:  2003-06-14       Impact factor: 4.599

Review 10.  Oxidative stress, lens gap junctions, and cataracts.

Authors:  Viviana M Berthoud; Eric C Beyer
Journal:  Antioxid Redox Signal       Date:  2009-02       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.